If increased catalytic rates conferred among some IDH1 mutants can indeed lead to higher D2HG concentrations in tumor models, understanding the impact of these mutations on tumor growth rates, epigenetic, and transcriptomic profiles can ultimately help us better predict patient prognosis. The gene discussed is IDH1; the disease is neoplasm.